The Artificial Pancreas Device System Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size for the artificial pancreas device system has seen significant growth recently. The market size is projected to increase from $1.81 billion in 2024 to $2.07 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%.
The artificial pancreas device system market is predicted to reach $3.48 billion by 2029, with a compound annual growth rate (CAGR) of 13.9%.
Download Your Free Sample of the 2025 Artificial Pancreas Device System Market Report and Uncover Key Trends Now!The drivers in the artificial pancreas device system market are:
• Rising inflow of investment in the sector
• Increasing government initiatives supporting clinical research
• Growing demand for automated systems in glycemic control
• Expanding research and development efforts by industry players, and higher geriatric population.
The artificial pancreas device system market covered in this report is segmented –
1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems
2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid
3) By End-User: Hospitals, Medical Centers, Other End-Users
The trends in the artificial pancreas device system market are:
• Rising product approvals are a major trend shaping the Artificial Pancreas Device System market.
• Increased partnerships and collaborations are beginning to influence the market.
• Increasing activities in tele consultancy for follow-up are a growing trend.
• Technological innovations and increased research and development activities are significantly influencing the market's future.
The major players in the artificial pancreas device system market are:
• Johnson & Johnson
• Abbott Laboratories
• Medtronic plc
• DexCom Inc
North America was the largest region in the artificial pancreas device system market in 2023